Masuda Sakue, Koizumi Kazuya, Makazu Makomo, Uojima Haruki, Kubota Jun, Kimura Karen, Nishino Takashi, Sumida Chihiro, Ichita Chikamasa, Sasaki Akiko, Shionoya Kento
Department of Gastroenterology Medicine Center, Shonan Kamakura General Hospital, 1370-1 Okamoto, Kamakura 247-8533, Japan.
Department of Gastroenterology, Internal Medicine, School of Medicine, Kitasato University, Sagamihara 252-0375, Japan.
J Clin Med. 2022 May 10;11(10):2697. doi: 10.3390/jcm11102697.
To prevent the increase of resistant bacteria, it is important to minimize the use of antimicrobial agents. Studies have found that administration for ≤3 days after successful endoscopic retrograde cholangiopancreatography (ERCP) is appropriate. Therefore, the present study aimed to verify if administration of antimicrobial agents can be further shortened to ≤2 days after ERCP. We divided 390 patients with mild and moderate cholangitis who underwent technically successful ERCP from January 2018 to June 2020 and had positive blood or bile cultures into two groups: antibiotic therapy within two days of ERCP (short-course therapy, SCT; n = 59, 15.1%), and for >3 days (long-course therapy, LCT; n = 331, 84.9%). The increased severity after admission and other outcomes were compared between the two groups, and the risk factors for increased severity were verified. There were no between-group differences in patient characteristics. Total length of hospital stay was shorter in SCT than in LCT, and other outcomes in SCT were not significantly different from those in LCT. Being 80 or older was a risk factor for increased severity; however, SCT was not associated with increased severity. Antimicrobial therapy for ≤2 days after successful ERCP is adequate in patients with mild and moderate acute cholangitis.
为防止耐药菌增加,尽量减少抗菌药物的使用非常重要。研究发现,在内镜逆行胰胆管造影术(ERCP)成功后给药≤3天是合适的。因此,本研究旨在验证ERCP后抗菌药物的给药时间是否可以进一步缩短至≤2天。我们将2018年1月至2020年6月期间接受了技术上成功的ERCP且血培养或胆汁培养呈阳性的390例轻中度胆管炎患者分为两组:ERCP后两天内进行抗生素治疗(短疗程治疗,SCT;n = 59,15.1%),以及治疗超过3天(长疗程治疗,LCT;n = 331,84.9%)。比较两组患者入院后病情严重程度增加情况及其他结局,并验证病情严重程度增加的危险因素。两组患者的特征无组间差异。SCT组的住院总时长比LCT组短,且SCT组的其他结局与LCT组无显著差异。年龄在80岁及以上是病情严重程度增加的一个危险因素;然而,SCT与病情严重程度增加无关。对于轻中度急性胆管炎患者,ERCP成功后抗菌治疗≤2天是足够的。